#Influenza and Other Respiratory Viruses Research #References (AMEDEO, May 2 '26)

 

Biochem Biophys Res Commun

1. SAKTHI P, Arun K, Priya D
   Integrative network pharmacology and molecular simulation analysis reveals the therapeutic potential of Coscinium fenestratum alkaloids against SARS-CoV-2.
   Biochem Biophys Res Commun. 2026;817:153681.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

2. TOZDUMAN B, Gulle BT
   Influenza Vaccination Coverage and Determinants of Vaccination Among Older Adults in Turkey.
   Epidemiol Infect. 2026 Apr 30:1-17. doi: 10.1017/S0950268826101563.
   PubMed        
   
   

   
   J Gen Virol

3. CHIANG HL, Lin HT, Chen WY, Liang KH, et al
   Broadly neutralizing monoclonal antibodies derived from mRNA LNP immunization exhibit potent neutralizing ability against JN.1, KP.3.1.1 and XEC new Omicron variants.
   J Gen Virol. 2026;107:002251.
   PubMed         Abstract available
   
   

   
   J Immunol

4. BENEZECH S, Picq L, Villard M, Rousseaux N, et al
   Single-cell analysis identifies CPT1a-associated metabolic remodeling in human NK cells during COVID-19.
   J Immunol. 2026;215:vkag036.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. O'HALLORAN A, Hood N, Ujamaa D, Merced-Morales A, et al
   Effects of age and birth cohort on influenza A virus subtype-specific hospitalization rates, United States 2010-2025.
   J Infect Dis. 2026 Apr 27:jiag232. doi: 10.1093.
   PubMed         Abstract available
   
   
6. ISHIKAWA S, Okada N, Fukui Y, Ueha R, et al
   Respiratory Syncytial Virus-Mediated Gas6/Axl Axis Induces Hyporesponsive Macrophages to Promote Pneumococcal Proliferation in the Nasopharynx.
   J Infect Dis. 2026;233:674-684.
   PubMed         Abstract available
   
   
7. ESNEAU C, Boettiger D, Leask S, Bryant NE, et al
   The Pandemic Respiratory Virus Epidemiological Surveillance Trial - A Self-swab Surveillance System for Respiratory Viruses Nested Within FluTracking.
   J Infect Dis. 2026;233:e1031-e1039.
   PubMed         Abstract available
   
   
8. KLAASSEN F, Swartwood NA, Chitwood MH, Lopes R, et al
   National- and State-level SARS-CoV-2 Immunity Trends From January 2020 to December 2023: a Mathematical Modeling Analysis.
   J Infect Dis. 2026;233:714-724.
   PubMed         Abstract available
   
   

   
   J Virol

9. DAINES R, Sadeyen J-R, Chang P, Iqbal M, et al
   Mapping hemagglutinin residues driving antigenic diversity in H5Nx avian influenza viruses.
   J Virol. 2026 Apr 30:e0009526. doi: 10.1128/jvi.00095.
   PubMed         Abstract available
   
   

   
   Lancet

10. DU X, Anderson CS
    Off-target benefits of influenza vaccination in cardiovascular disease - Authors' reply.
    Lancet. 2026;407:1600.
    PubMed        
    
    
11. FROBERT O, Pedersen IB, Hjelholt AJ, Erikstrup C, et al
    Off-target benefits of influenza vaccination in cardiovascular disease.
    Lancet. 2026;407:1599-1600.
    PubMed        
    
    

    
    Pediatrics

12. ENGSTROM EE, Kaplan SL, Barson WJ, Lin PL, et al
    Pneumococcal Pneumonia in Hospitalized Children: 2017-2023.
    Pediatrics. 2026;157:e2025073196.
    PubMed         Abstract available
    
    
13. KUTZ C, Alarcon-Andrade G, Aguilera E, Garfias C, et al
    Incidence and Severity of Type 1 Diabetes in Children Through the COVID-19 Pandemic in Chile.
    Pediatrics. 2026 Apr 23:e2025072191. doi: 10.1542/peds.2025-072191.
    PubMed         Abstract available
    
    
14. JACOBSON KB, Merchant M, Fireman B, Klein NP, et al
    SARS-CoV-2 Vaccination Before and During Pregnancy and Prevention of Infant COVID-19 Infection.
    Pediatrics. 2026 Apr 22:e2025073000. doi: 10.1542/peds.2025-073000.
    PubMed         Abstract available
    
    
15. LOWENSTEIN C, Kamdar N, Rehkopf DH
    Trends in Youth Mental Health Among Patients in Family Medicine Practices: 2017-2023.
    Pediatrics. 2026;157:e2025072305.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

16. MOSS R, Tobin RJ, O'Hara-Wild M, Adekunle AI, et al
    Ensemble forecasts of COVID-19 activity to support Australia's pandemic response: 2020-22.
    PLoS Comput Biol. 2026;22:e1014199.
    PubMed         Abstract available
    
    
17. PAMORNCHAINAVAKUL N, Schroeder DC, VanderWaal K
    QoALa: A comprehensive workflow for viral quasispecies diversity comparison using long-read sequencing data.
    PLoS Comput Biol. 2026;22:e1014208.
    PubMed         Abstract available
    
    

    
    PLoS One

18. THIPAYAMASKOMON C, Grimaud O, Tattevin P, Lamhaut L, et al
    High-speed trains versus air transport vectors for mass transfers of critically ill patients: The TRANSCOV cohort study.
    PLoS One. 2026;21:e0348090.
    PubMed         Abstract available
    
    
19. HU R, Valdivia A, White T, Ju W, et al
    Poldip2 deficiency attenuates lung disease severity in a mouse model of COVID-19.
    PLoS One. 2026;21:e0348065.
    PubMed         Abstract available
    
    
20. OKADA Y, Nishiura H
    Changes in life expectancy and life span equality during the COVID-19 epidemic in 2020-22 in Japan.
    PLoS One. 2026;21:e0345579.
    PubMed         Abstract available
    
    
21. RODRIGUEZ-CRESPO JJ, Gutierrez-Leon E, Dammann-Beltran P, Seaman-Gomez JA, et al
    Outcomes in acute pulmonary embolism and their association with adherence to international recommendations around COVID-19 pandemic-induced hospital-strain: The experience in a Mexican tertiary care center.
    PLoS One. 2026;21:e0347761.
    PubMed         Abstract available
    
    
22. HASHEMPOUR Y, Zazouli MA, Jaafarzadeh N, Valadan R, et al
    Integrated monitoring of enveloped viruses in hospital environments: Detection, persistence, and implications for infection control.
    PLoS One. 2026;21:e0345644.
    PubMed         Abstract available
    
    
23. SU B, Sun Z, Chen R, Liu H, et al
    Association between psychological distress, lifestyle and career planning on health-related quality of life among the university students during school closure of COVID-19 pandemic in China.
    PLoS One. 2026;21:e0347032.
    PubMed         Abstract available
    
    
24. WANG M, Laison EKE, Philippsen T, Ghaemi S, et al
    Mechanistic modelling of highly pathogenic avian influenza: A scoping review revealing critical gaps in cross-species transmission models.
    PLoS One. 2026;21:e0347929.
    PubMed         Abstract available
    
    
25. FATHELRAHMAN E, Mohamed Ali M, Challa TG, Osman R, et al
    Modeling and assessing Highly Pathogenic Avian Influenza (HPAI) spread, epidemiological control measures, and cost.
    PLoS One. 2026;21:e0340004.
    PubMed         Abstract available
    
    
26. BASHIR K, Ouedraogo MO, Dharma C, Sobers M, et al
    Strengthening access to and confidence in COVID-19 vaccines among equity-deserving populations across Canada: An exploratory qualitative study.
    PLoS One. 2026;21:e0301953.
    PubMed         Abstract available
    
    
27. KO CC, Wu JY, Hung KC, Liao SW, et al
    The impact of COVID-19 vaccination on long-term risk of new-onset atrial fibrillation/flutter after COVID-19 infection: A retrospective cohort study.
    PLoS One. 2026;21:e0348133.
    PubMed         Abstract available
    
    
28. LIU C, Yang L, Lei J
    CMAP-Fusion: A cross-modal feature selection and model pruning framework for laboratory and imaging data.
    PLoS One. 2026;21:e0346875.
    PubMed         Abstract available
    
    
29. DAS N, Konduru L, Dahia SS, Sagnika S, et al
    The stress reduction potential of Bhagavad Gita and Yoga for healthcare workers during the COVID-19 pandemic: A randomized controlled trial.
    PLoS One. 2026;21:e0347320.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

30. RODRIGUEZ HERNANDEZ CJ, Cruz-Cruz A, Shrestha CL, Terekhova M, et al
    Gingipain proteases from the bacterium Porphyromonas gingivalis confer protection against airway viral infection.
    Proc Natl Acad Sci U S A. 2026;123:e2503100123.
    PubMed         Abstract available
    
    
31. HUANG KA, Nguyen HTV, Chen YY, Wu KJ, et al
    Broad neutralization of influenza B hemagglutinin antibodies via receptor mimicry and glycan engagement.
    Proc Natl Acad Sci U S A. 2026;123:e2532989123.
    PubMed         Abstract available
    
    
32. ZHANG Y, Wang C, Zheng Y, Chen F, et al
    An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2026;123:e2519857123.
    PubMed         Abstract available
    
    
33. DE LACY N, Lam WY, Collins T, Danks D, et al
    A century of suicide: Insights from long-term data in the United States.
    Proc Natl Acad Sci U S A. 2026;123:e2519951123.
    PubMed         Abstract available
    
    

    
    Vaccine

34. LIU Y, Jia M, Mu X, Jiang B, et al
    Designing equitable influenza vaccination services for older adults in rural China: A discrete choice experiment.
    Vaccine. 2026;82:128590.
    PubMed         Abstract available
    
    
35. SILVA LL, Lopes VDS, da Silva DCB, Nemer CRB, et al
    Global overview of vaccine trust: Evidence from a scoping review.
    Vaccine. 2026;79:128482.
    PubMed         Abstract available
    
    
36. JAMES E, Christie S, Boye B, Githieya D, et al
    How to leverage social media to build confidence in COVID-19 vaccines: findings and lessons learned from nationwide campaigns in four countries.
    Vaccine. 2026;79:128475.
    PubMed         Abstract available
    
    
37. MALDEN DE, Ackerson BK, Gee J, Peryer MA, et al
    Self-reported reactogenicity of RSV vaccines among older adults: a post-licensure study within a large integrated healthcare system in Southern California.
    Vaccine. 2026;79:128493.
    PubMed         Abstract available
    
    
38. FANTIN R, Das S, Loria V, Calderon A, et al
    Hybrid immunity provides stronger protection against SARS-CoV-2 infection than vaccination alone: Evidence from a population-based active monitoring study.
    Vaccine. 2026;79:128506.
    PubMed         Abstract available
    
    
39. DENG L, Barton B, Choi P, Clarke L, et al
    Clinical, psychological and quality of life outcomes up to 12-months following thrombosis with thrombocytopenia syndrome after ChAdOx1-S (AZD1222) vaccination in Australia.
    Vaccine. 2026;79:128501.
    PubMed         Abstract available
    
    
40. BRIGGS K, Gingerich MC, Gingerich A, Johnson SK, et al
    Intranasal PIV5-vectored SARS-COV-2 KP.2 vaccine protects against homologous and heterologous challenge in mice and hamsters.
    Vaccine. 2026;79:128490.
    PubMed         Abstract available
    
    
41. AZEEZ R, Ames SR, Lotoski LC, Winsor GL, et al
    Predictors of SARS-CoV-2 anti-Spike IgG antibody levels following two COVID-19 vaccine doses among children and adults in the Canadian CHILD Cohort.
    Vaccine. 2026;79:128342.
    PubMed         Abstract available
    
    
42. ROOYAKKERS A, Ye L, Cahn PE, Ruiz-Palacios GM, et al
    Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.
    Vaccine. 2026;79:128424.
    PubMed         Abstract available
    
    
43. STRAUTINS K, Foong R, Carcione D, Spencer P, et al
    Post-licensure safety monitoring of nirsevimab in Western Australia 2024.
    Vaccine. 2026;79:128468.
    PubMed         Abstract available
    
    
44. AIZAWA Y, Shobugawa Y, Tachikawa J, Ikuse T, et al
    Effectiveness of the COVID-19 messenger RNA vaccine against symptomatic omicron infection in children aged 6 months to 11 years in Japan.
    Vaccine. 2026;79:128474.
    PubMed         Abstract available
    
    
45. LLOYD PC, Shah PB, Zhang HT, Shah N, et al
    Safety monitoring of health outcomes following RSVPreF3 + AS01 and RSVPreF vaccination among Medicare beneficiaries aged 65 years and older in the United States, 2023-2024.
    Vaccine. 2026;79:128459.
    PubMed         Abstract available
    
    
46. MADNI SA, Olson CK, Zauche LH, Machefsky A, et al
    Risk of perinatal death and preterm birth among an observational cohort of women vaccinated against SARS-CoV-2 in pregnancy: CDC COVID-19 vaccine pregnancy registry.
    Vaccine. 2026;79:128461.
    PubMed         Abstract available
    
    
47. GIOVANATTI A, Shapiro AE
    Anticipating tuberculosis vaccine acceptability in Kenya and South Africa: a narrative review of behavioral and social drivers and strategies to optimize acceptability.
    Vaccine. 2026;79:128457.
    PubMed         Abstract available
    
    
48. GUARDALINI LGO, Martins IM, Bernardino TC, Quintilio W, et al
    Non-clinical analysis of virus-like particles (VLP) containing SARS-CoV-2 vaccine antigens.
    Vaccine. 2026;79:128406.
    PubMed         Abstract available
    
    
49. DURIER C, Benhamouda N, Besbes A, Lefebvre M, et al
    Ancestral Wuhan SARS-CoV-2 anti-spike CD4(+) T cells predict protection from symptomatic omicron breakthrough infection.
    Vaccine. 2026;79:128425.
    PubMed         Abstract available
    
    
50. VISKUPIC F, Wiltse DL, Liebl Z, Kinslow T, et al
    The prevalence and nature of anti-vaccination legislation in ten midwestern states: Implications for public health and policy.
    Vaccine. 2026;79:128452.
    PubMed         Abstract available
    
    
51. DRISLANE S, Lake J, Attwell K
    Learning from government communication strategies to promote infant RSV immunisation: A cross-national study of France, Luxembourg, Spain, and Australia.
    Vaccine. 2026;79:128432.
    PubMed         Abstract available
    
    
52. CABIESES B, Obach A, Madrid P, Blukacz A, et al
    Mapping the continuum of COVID-19 vaccine acceptance and hesitancy in Chile: Insights from qualitative research among nationals and migrants.
    Vaccine. 2026;79:128433.
    PubMed         Abstract available
    
    
53. LU PJ, Hung MC, Srivastav A, Kriss JL, et al
    RSV vaccination uptake by the end of the 2024-25 respiratory virus season among adults aged 60-74 years at increased risk of severe RSV and adults aged >/=75 years.
    Vaccine. 2026;79:128427.
    PubMed         Abstract available
    
    
54. JANSSEN RS, Coffman RL
    A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonists.
    Vaccine. 2026;79:128437.
    PubMed         Abstract available
    
    
55. IRVING SA, Crane B, Daley MF, Dixon BE, et al
    2023-2024 COVID-19 vaccination coverage in pregnancy in ten healthcare delivery organizations in the United States.
    Vaccine. 2026;79:128441.
    PubMed         Abstract available
    
    
56. COSTANTINO V, Notaras A, MacIntyre CR
    Long COVID in children in Australia and the potential impact of vaccination.
    Vaccine. 2026;79:128442.
    PubMed         Abstract available
    
    
57. LLANES-KIDDER C, Gaythorpe K, Rawson T
    Sociodemographic factors influencing COVID-19 vaccine uptake and dropout rates in England.
    Vaccine. 2026;79:128477.
    PubMed         Abstract available
    
    
58. MCEVOY R, Hervol JR, Zhang Y, Wagner EM, et al
    A modified self-controlled case series on mortality risk following primary series doses of COVID-19 vaccines in U.S. Medicare beneficiaries aged 65 years and older.
    Vaccine. 2026;79:128460.
    PubMed         Abstract available

Prior #immunity to seasonal #influenza #H3N2 virus confers varying levels of cross - #protection against challenge with clade 2.3.4.4b #H5N1, #H7N9, or #H9N2 virus in a #ferret model

 

ABSTRACT

Evaluating how prior immunity to seasonal influenza viruses influences subsequent zoonotic influenza A virus (IAV) infection in animal models is critical for pandemic preparedness. In this study, we investigated the cross-protective effect of pre-existing A(H3N2) immunity in ferrets challenged with three distinct subtypes of zoonotic IAVs: low pathogenic A(H7N9) and A(H9N2) viruses, and highly pathogenic clade 2.3.4.4b A(H5N1) virus. Our results show that A(H3N2) preimmunity conferred some protection against A(H5N1) and A(H9N2) virus infection, as evidenced by more rapid viral clearance in the upper respiratory tract, reduced virus shedding in the nasal wash on select days post-inoculation, and a lowered frequency of viral detection in specific tissues compared with naive animals. In contrast, A(H3N2) preimmunity provided minimal cross-protection against A(H7N9) infection, as weight loss and viral dissemination in tissues were not significantly reduced in A(H3N2) preimmune ferrets relative to naive animals. These findings highlight the variable breadth and magnitude of cross-protection elicited by prior seasonal IAV immunity against zoonotic influenza virus challenges in the ferret model. Seasonal influenza A(H3N2) preimmunity provided differing levels of cross-protection against zoonotic influenza A virus infections in ferrets.

Source: 

Link: https://journals.asm.org/doi/10.1128/spectrum.03974-25

____

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 25 '26)

 

Ann Intern Med

1. LIM SY, Lee J, Chang E, Kwon JS, et al
   Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 : A Randomized Clinical Trial.
   Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-04883.
   PubMed         Abstract available
   
   
2. QASEEM A, Obley AJ, Yost J, Abraham GM, et al
   Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3).
   Ann Intern Med. 2026 Feb 10. doi: 10.7326/ANNALS-25-03766.
   PubMed         Abstract available
   
   
3. SOMMER I, Dobrescu A, Gadinger A, Sharifan A, et al
   Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3).
   Ann Intern Med. 2026 Feb 10. doi: 10.7326/ANNALS-25-03691.
   PubMed         Abstract available
   
   

   
   Biochemistry

4. MEDEIROS-SILVA J, Zhang Y, Hong M
   Phosphatidylinositol Interactions with the SARS-CoV-2 Envelope Protein Investigated by Lipid (13)C Labeling and Solid-State NMR.
   Biochemistry. 2026;65:1178-1191.
   PubMed         Abstract available
   
   

   
   J Infect

5. COX SN, Bennett JC, Casto AM, Hoffman KL, et al
   INFLUENZA HOUSEHOLD TRANSMISSION AND GENOMIC DIVERSITY IN THE UNITED STATES: A PROSPECTIVE COHORT STUDY, 2022-2024.
   J Infect. 2026 Apr 20:106748. doi: 10.1016/j.jinf.2026.106748.
   PubMed         Abstract available
   
   

   
   J Virol

6. ZHANG R, Jian X, Zhang Y, Sun Y, et al
   The oral nucleoside analogue inhibitor VV251 effectively inhibits coinfection by respiratory syncytial virus and influenza A virus.
   J Virol. 2026 Apr 21:e0000626. doi: 10.1128/jvi.00006.
   PubMed         Abstract available
   
   
7. YILDIZ S, El Zahed SS, Villalon-Letelier F, Wang Q, et al
   Re-engineering segment 8 facilitates generation of a versatile live-attenuated influenza A virus vector platform for secretory protein delivery.
   J Virol. 2026 Apr 21:e0034726. doi: 10.1128/jvi.00347.
   PubMed         Abstract available
   
   
8. KONG W, Zhang J, Song Y, Song J, et al
   Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity.
   J Virol. 2026 Mar 30:e0027026. doi: 10.1128/jvi.00270.
   PubMed         Abstract available
   
   
9. XIU R, Wang Y, Cai W, Wang Q, et al
   Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or M(pro) inhibitors.
   J Virol. 2026 Mar 30:e0007626. doi: 10.1128/jvi.00076.
   PubMed         Abstract available
   
   
10. BRENNAN JW, Wang G, Connor S, Wang X, et al
    A respiratory syncytial virus trailer sequence modulates viral replication and the generation and propagation kinetics of copy-back defective viral genomes.
    J Virol. 2026;100:e0018426.
    PubMed         Abstract available
    
    
11. ADAM A, Wu W, Jones MC, Hao H, et al
    Respiratory syncytial virus infection induces heterologous protection against SARS-CoV-2 through gammadelta T cell-mediated trained immunity and the activation of SARS-CoV-2-reactive mucosal T cells.
    J Virol. 2026 Mar 18:e0165825. doi: 10.1128/jvi.01658.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

12. BELL JM, Barbre K, Meng L, Lape-Newman B, et al
    Influenza Vaccination Coverage Among Nursing Home Residents and Health Care Personnel - United States, 2024-25 Influenza Season.
    MMWR Morb Mortal Wkly Rep. 2026;75:195-201.
    PubMed         Abstract available
    
    

    
    N Engl J Med

13. BUTLER CC, Pinto AD, Harris V, Holmes J, et al
    Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
    N Engl J Med. 2026;394:1583-1594.
    PubMed         Abstract available
    
    

    
    Pediatrics

14. SEGEV N, Wilson E, Moehlman M, Corathers SD, et al
    Unmasking Adrenal Insufficiency: Adrenal Crisis Triggered by Influenza-Associated Encephalitis.
    Pediatrics. 2026 Apr 22:e2025072983. doi: 10.1542/peds.2025-072983.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

15. LI Y, Nielsen BF, Levin SA, Te Velthuis AJW, et al
    Spatio-temporal modelling of in vitro influenza A virus infection: The impact of defective interfering particles on the type I interferon response.
    PLoS Comput Biol. 2026;22:e1014198.
    PubMed         Abstract available
    
    
16. WHITE LA, Leon TM
    Forecastability of infectious disease time series: are some seasons and pathogens intrinsically more difficult to forecast?
    PLoS Comput Biol. 2026;22:e1014175.
    PubMed         Abstract available
    
    

    
    PLoS One

17. ORTEGA-MARTIN E, Alvarez-Galvez J
    Understanding quality-of-life patterns in long COVID: How Symptoms and socioeconomic conditions shape patient wellbeing.
    PLoS One. 2026;21:e0347743.
    PubMed         Abstract available
    
    
18. CHAVES SS, Castells VB, Mira-Iglesias A, Puig-Barbera J, et al
    Rhinovirus/enterovirus contribution to respiratory-associated hospitalizations in adults during respiratory seasons in Spain: A 6-year prospective study.
    PLoS One. 2026;21:e0347659.
    PubMed         Abstract available
    
    
19. LEE J, Bajiya VP, Jung E
    Vaccination scenario-based study on seasonal influenza in Republic of Korea.
    PLoS One. 2026;21:e0322686.
    PubMed         Abstract available
    
    
20. PIRZADA P, Wilde A, Doherty GH, Harris-Birtill D, et al
    Understanding older adults' perception, acceptance, and adoption of smart home technologies.
    PLoS One. 2026;21:e0345563.
    PubMed         Abstract available
    
    
21. FANG Z, Xu H, Mu Y
    Risk-taking responses to crash experience: Evidence from China.
    PLoS One. 2026;21:e0347543.
    PubMed         Abstract available
    
    
22. GARZA J, Sebastian R, Cover B, Sanchez A, et al
    Nicotine dependence among critically ill COVID-19 patients: A population-based cohort study.
    PLoS One. 2026;21:e0308776.
    PubMed         Abstract available
    
    
23. MCDONALD C, Grajales AG, Yahia NA, Fisman D, et al
    Healthcare resource utilization and cost burden of COVID-19 according to vaccination status in adults in Ontario, Canada, 2021-2023.
    PLoS One. 2026;21:e0344690.
    PubMed         Abstract available
    
    
24. LOVATO N, Appleton SL, Reynolds AC, Gill TK, et al
    Relationships between pre-pandemic mental health, sociodemographic factors and health behaviours in older adults during the acute onset of COVID-19 in Australia: A descriptive analysis.
    PLoS One. 2026;21:e0346787.
    PubMed         Abstract available
    
    
25. AUDUREAU E, Jean C, Layese R, Neuraz A, et al
    Association between parenthood and survival among 30,386 patients hospitalized with COVID-19.
    PLoS One. 2026;21:e0346679.
    PubMed         Abstract available
    
    
26. IPEKCI AM, Hodel EM, Filsinger M, Wegmuller S, et al
    Who would take part in a pandemic preparedness cohort study? The role of vaccine-related affective polarisation: Cross-sectional survey.
    PLoS One. 2026;21:e0346420.
    PubMed         Abstract available
    
    
27. YANG Z, Imouza A, Puelma Touzel M, Amadoro C, et al
    Regional and temporal patterns of partisan polarization during the COVID-19 pandemic in the United States and Canada.
    PLoS One. 2026;21:e0347327.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

28. SANDERS CG, Liu M, Fusco JA, Ohl EM, et al
    Efficient replication of influenza D virus in the human airway underscores zoonotic potential.
    Proc Natl Acad Sci U S A. 2026;123:e2530325123.
    PubMed         Abstract available
    
    

    
    Vaccine

29. ROBERTSON AH, Wolf AS, Fossum E, Solum G, et al
    Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infections.
    Vaccine. 2026;80:128511.
    PubMed         Abstract available
    
    
30. DLOUHY P, Petras M, Lesna IK, Macalik R, et al
    Transient elevation of NT-proBNP after mRNA COVID-19 vaccination in healthy adults: A longitudinal biomarker analysis.
    Vaccine. 2026;80:128535.
    PubMed         Abstract available
    
    
31. VAN DE BURGWAL LHM, Pronker ES, Herz J
    Australia's vaccine legacy: Time for a boost? Mapping an innovation system in a fragmented data environment.
    Vaccine. 2026;80:128525.
    PubMed         Abstract available
    
    
32. WU D, Liu K
    Cost and effectiveness of COVID-19 vaccination strategies during the 2023 post-reopening omicron wave in Xinjiang, Western China: Evidence from SIR and Markov models.
    Vaccine. 2026;80:128536.
    PubMed         Abstract available
    
    
33. MAEDA H, Saito N, Igarashi A, Ishida M, et al
    Effectiveness of JN.1-adapted COVID-19 vaccine against medically attended SARS-CoV-2 infection and COVID-19 hospitalization in adults in Japan, from October 2024 to April 2025: VERSUS.
    Vaccine. 2026;80:128544.
    PubMed         Abstract available
    
    
34. MORO PL, Romanson B, Marquez P, Zhang B, et al
    Adverse events after Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System, 2024-2025, United States.
    Vaccine. 2026;80:128547.
    PubMed         Abstract available
    
    
35. QUINTANAR-SOLARES M, Fleming JA, Musau W, Mulati F, et al
    RSV ready? Exploring feasibility and acceptability of RSV immunization options in low- and middle-income countries.
    Vaccine. 2026;80:128550.
    PubMed         Abstract available
    
    
36. KITANO T, Hashimoto E, Sado T, Yoshida S, et al
    Maternal effectiveness of respiratory syncytial virus using multicenter healthcare records: A retrospective cohort study.
    Vaccine. 2026;80:128566.
    PubMed         Abstract available
    
    
37. ZHANG L, Lin T, Wang M, Ma X, et al
    Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial.
    Vaccine. 2026;82:128588.
    PubMed         Abstract available
    
    
38. FOLEGATTI PM, Pepin S, Tabar C, Fries K, et al
    Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study.
    Vaccine. 2026;82:128582.
    PubMed         Abstract available
    
    
39. RICE E, Cheng AC, Britton PN, Carr J, et al
    Influenza epidemiology, treatment and prevention in Australian children: Trends from 6 years of PAEDS-FluCAN influenza surveillance (2019-2024).
    Vaccine. 2026;82:128592.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 19 '26)

 

Biochem Biophys Res Commun

1. CHEN M, Chen W, Jiang X, Liang S, et al
   Virtual screening targeting the conserved domain of the IAV M2 protein reveals the potential broad-spectrum anti-IAV activity of ajmaline.
   Biochem Biophys Res Commun. 2026;814:153643.
   PubMed         Abstract available
   
   

   
   BMJ

2. DAVIES SR, Davies AL, Higgins JPT, Caldwell DM, et al
   Effectiveness of interventions to increase vaccine uptake: component network meta-analysis.
   BMJ. 2026;393:e087578.
   PubMed         Abstract available
   
   

   
   Drug Saf

3. HWANG CS, Lu Z, Russo M, Zakoul H, et al
   Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 Pandemic.
   Drug Saf. 2026;49:519-528.
   PubMed         Abstract available
   
   
4. COATES MM, Rowe SL, Sullivan SG, Munoz FM, et al
   Assessing the Use of Medical Insurance Claims and Electronic Health Records to Measure COVID-19 Vaccination During Pregnancy.
   Drug Saf. 2026;49:567-580.
   PubMed         Abstract available
   
   
5. RACHWAL O, Gutierrez-Lobon M, Cueto NS, Ventura AN, et al
   Evaluating COVID-19 Vaccine Masking and Unmasking Methods in Two National Pharmacovigilance Databases.
   Drug Saf. 2026;49:581-590.
   PubMed         Abstract available
   
   
6. JAJOU R, van Puijenbroek E, Overbeek J, Hek K, et al
   GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands.
   Drug Saf. 2026;49:529-539.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

7. GONZALES BE, Ochoa TJ, van der Sande MAB
   Inequalities in complete pneumococcal vaccination among Peruvian children before and after the COVID-19 pandemic: An evaluation using demographic and health surveys from 2018 to 2023.
   Epidemiol Infect. 2026;154:e49.
   PubMed         Abstract available
   
   
8. KIMURA M, Asai Y, Tsuzuki S, Shimizu Y, et al
   Effectiveness of voluntary PCR testing against COVID-19 spread in remote Japanese islands.
   Epidemiol Infect. 2026;154:e48.
   PubMed         Abstract available
   
   

   
   J Virol Methods

9. ASGHARI M, Golalipour M, Memarian A, Farazmandfar T, et al
   Presentation of multiple copies of a non-dominant surface epitope by circular RNA effectively induce an immune response against SARS-CoV-2.
   J Virol Methods. 2026;343:115378.
   PubMed         Abstract available
   
   
10. CHIBA S
    Therapeutic mechanisms of early oseltamivir administration in the management of mild COVID-19 through the sympathetic nervous system: A scoping review.
    J Virol Methods. 2026;343:115386.
    PubMed         Abstract available
    
    

    
    Lancet

11. JOHANSEN ND, Seco JP, Martinon-Torres F, Biering-Sorensen T, et al
    Unclear benefits of higher doses of influenza vaccine - Authors' reply.
    Lancet. 2026;407:1426.
    PubMed        
    
    
12. FLAHAULT A
    Unclear benefits of higher doses of influenza vaccine.
    Lancet. 2026;407:1425-1426.
    PubMed        
    
    

    
    PLoS Biol

13. SOLA I, Zuniga S
    New transcription signals in SARS-CoV-2 reshape virus-host interactions.
    PLoS Biol. 2026;24:e3003744.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

14. JEONG YD, Hart WS, Ishikane M, Kim KS, et al
    Identifying the optimal rapid antigen test for screening and determining the end of isolation: A modeling study.
    PLoS Comput Biol. 2026;22:e1013102.
    PubMed         Abstract available
    
    
15. ANOKYE F, Li MWZ, Walker S, Hurford A, et al
    Quantifying SARS-CoV-2 Omicron variant spread and the impact of non-pharmaceutical interventions in Newfoundland and Labrador, Canada.
    PLoS Comput Biol. 2026;22:e1013562.
    PubMed         Abstract available
    
    

    
    PLoS One

16. ABDELGHANY M, Yu F, Rennard S, Gwon Y, et al
    Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease.
    PLoS One. 2026;21:e0346878.
    PubMed         Abstract available
    
    
17. BERBER E, Hanley HB, Gamez BM, Ross TM, et al
    Assessment of hemagglutinin-inhibition activity following influenza vaccination during the 2022-2023, 2023-2024, and 2024-2025 seasons.
    PLoS One. 2026;21:e0347314.
    PubMed         Abstract available
    
    
18. MURALIDHAR K, Ngaybe MGB, Pope B, Nanjaiah S, et al
    Behavioural and Social Drivers (BeSD) of COVID-19 vaccination for children: A cross-sectional study of parental vaccine confidence and intent in Mysore, India.
    PLoS One. 2026;21:e0316877.
    PubMed         Abstract available
    
    
19. BHUPATHI M, Hegde S, Molloy JC, Devarapu GCR, et al
    MobileLAMP: A low-cost, portable incubation device for isothermal nucleic acid amplification.
    PLoS One. 2026;21:e0346874.
    PubMed         Abstract available
    
    
20. SHIMAZU Y, Isoda N, Hiono T, Hew YL, et al
    Evaluation of therapeutic efficacy of baloxavir marboxil against high pathogenicity avian influenza virus infection in duck model.
    PLoS One. 2026;21:e0347205.
    PubMed         Abstract available
    
    
21. GANGAT R, Ngah V, Tawonga R, Blanford JI, et al
    Spatial and temporal patterns of SARS-CoV-2 infection in uMgungundlovu, KwaZulu-Natal, South Africa.
    PLoS One. 2026;21:e0317648.
    PubMed         Abstract available
    
    
22. VAN DUINKERKEN A, van der Velden PG, Duckers MLA, Baliatsas C, et al
    Revisiting the exposure criterion for PTSD: Using the COVID-19 pandemic as an opportunity to assess measurement invariance of PTSD symptoms across event types.
    PLoS One. 2026;21:e0347315.
    PubMed         Abstract available
    
    
23. KITTUR ME, Jones BDM, Imran S, Wang W, et al
    Impact of the COVID-19 pandemic on adults accessing specialist psychiatric care: A cross-sectional Canadian analysis.
    PLoS One. 2026;21:e0346913.
    PubMed         Abstract available
    
    
24. CASJENS S, Hovanec J, Glaser N, Massag J, et al
    Occupational risk factors for depression and anxiety symptoms: Insights from a large cohort study during and after the SARS-CoV-2 pandemic.
    PLoS One. 2026;21:e0346871.
    PubMed         Abstract available
    
    
25. JIANG KP, Bennett S, Yager P
    Heat-actuated valve implementation in a point-of-care, paper-based microfluidic device for infectious disease detection.
    PLoS One. 2026;21:e0344750.
    PubMed         Abstract available
    
    
26. ABBAS U, Laghari RN, Ahmed I, Musawwir UA, et al
    Acute SARS-CoV-2 viral load and systemic inflammation are associated with neuropsychiatric and musculoskeletal symptoms in long COVID.
    PLoS One. 2026;21:e0346978.
    PubMed         Abstract available
    
    
27. OZATO N, Hori S, Miyai N, Takase H, et al
    Association of visceral fat and plasmacytoid dendritic cell-derived interferon alpha with SARS-CoV-2 infection.
    PLoS One. 2026;21:e0344870.
    PubMed         Abstract available
    
    
28. DIAS GF, Fan C, Han M, Wang X, et al
    COVID-19 in hemodialysis patients: New insights into metabolomic profile dynamics from 60 days pre- to 60 days post-diagnosis.
    PLoS One. 2026;21:e0346687.
    PubMed         Abstract available
    
    
29. MOHTASHAM F, Hashemi Nazari SS, Pourhoseingholi MA, Kavousi K, et al
    Hybrid feature-selection and diversity-guided stacking framework for interpretable ensemble learning: Application to COVID-19 mortality prediction.
    PLoS One. 2026;21:e0341198.
    PubMed         Abstract available
    
    
30. LEE SJ, Kim J, Han M, Lee JA, et al
    Distinct plasma cytokine and chemokine profiles in severe COVID-19 and septic shock.
    PLoS One. 2026;21:e0347126.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

31. GOLDMAN N, Pebley AR
    The Latino health experience: Past and future.
    Proc Natl Acad Sci U S A. 2026;123:e2530795123.
    PubMed         Abstract available
    
    
32. HUOT M, Wang D, Shakhnovich E, Monasson R, et al
    Constrained evolutionary funnels shape viral immune escape.
    Proc Natl Acad Sci U S A. 2026;123:e2536956123.
    PubMed         Abstract available
    
    
33. FARIAS A, Bridgeman VL, Rodrigues FS, Puttur F, et al
    Type I interferons induced upon respiratory viral infection impair lung metastatic initiation.
    Proc Natl Acad Sci U S A. 2026;123:e2412919123.
    PubMed         Abstract available
    
    

    
    Vaccine

34. HSIEH SM, Choi MJ, Chen YC, Cheng SY, et al
    Cost-effectiveness of vaccination of older adults with an MF59(R)-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in South Korea and Taiwan.
    Vaccine. 2026;80:128533.
    PubMed         Abstract available
    
    
35. ANYALECHI EG, Marquez PL, Rubin MN, Johannsen SP, et al
    Safety of seasonal inactivated influenza vaccines in children 6 months-17 years of age in the Vaccine Adverse Events Reporting System (VAERS) 2018-2023: before, during, and after the COVID-19 pandemic public health emergency.
    Vaccine. 2026;81:128569.
    PubMed         Abstract available
    
    

    
    Virology

36. SWIERKOT J, Tyczynska KM, Siemaszko J, Madej M, et al
    The association of selected genetic polymorphisms with adverse events following COVID-19 vaccination: a single-centre prospective observational cohort study.
    Virology. 2026;619:110876.
    PubMed         Abstract available
    
    
37. CHEN G, Liang D, Liu M, Lv Z, et al
    Theaflavins suppresses RSV infection by modulating the MAVS-I-IFN pathway.
    Virology. 2026;619:110872.
    PubMed         Abstract available
    
    
38. LIU R, Patterson L, Yeasmin M, Kim KH, et al
    Low-dose multivalent COVID-19 mRNA vaccines enhance broadly cross-reactive antibodies and protective immune responses of co-administered protein-based vaccines.
    Virology. 2026;619:110884.
    PubMed         Abstract available
    
    
39. WANG Z, Wongnak R, Oba M, Mizutani T, et al
    Omicron RBD expressed in E. coli outperforms mammalian-expressed S1 spike protein in generating highly neutralizing anti-SARS-CoV-2 antibodies in mice.
    Virology. 2026;619:110894.
    PubMed         Abstract available
    
    
40. RICHARDSON SAS, Boodhoo N, Bhat S, Wells J, et al
    Differential outcomes of viral co-infections with high pathogenicity avian influenza A(H5N6) and SARS-CoV-2 in mammalian in vitro systems.
    Virology. 2026;620:110912.
    PubMed         Abstract available
    

Cross - #protection against highly pathogenic avian #influenza #H5N1 virus from seasonal influenza #vaccines: a systematic review and meta-analysis of #ferret studies

 

ABSTRACT

The recent surge in spillover events of highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b to humans and mammals in North America has raised urgent pandemic concerns. Human H5N1 vaccines are unavailable in most countries. We synthesized data from ferret challenge trials to evaluate whether widely available seasonal influenza vaccines confer cross-protection against lethal H5N1 infection. We systematically searched PubMed, Embase, and Web of Science for ferret studies of lethal H5N1 challenge published up to 5 July 2025 (PROSPERO #CRD42024520346). Random-effects meta-analyses were conducted to compare vaccine efficacy (VE) of seasonal influenza vaccines and H5N1 vaccines against H5N1-related mortality. Seroprotection was defined as a neutralizing antibody titre of ≥1:40. We identified 35 studies (157 trials). Seasonal influenza vaccines without N1 did not confer significant cross-protection (five trials; VE 14.8%, 95% CI –3.6 to 30.0). In contrast, VE was 73% for N1-containing seasonal influenza vaccines (19 trials; 95% CI 54–84) and 77% for H5N1 vaccines overall (133 trials; 95% CI 72–82) (p = 0.52). The VE of N1-containing seasonal influenza vaccines was modestly lower than that of H5N1 vaccines with seroprotection (88%; 66 trials; 95% CI 84–91; p = 0.009), but comparable to H5N1 vaccines that did not achieve seroprotection (63%; 67 trials; 95% CI 52–71; p = 0.29). The VE of seasonal influenza vaccines against H5N1 was robust across sensitivity analyses, with no evidence of publication bias (p = 0.99). Seasonal influenza vaccines significantly reduce H5N1-associated mortality in ferret trials, suggesting the cross-protection potential of currently available vaccines. Human studies are warranted.

Source: 

Link: https://www.tandfonline.com/doi/full/10.1080/22221751.2026.2654278

____

#Vaccine-Elicited #Antibody Responses to #Influenza #H3N2 Subclade K

 

{Summary}

Influenza A(H3N2) subclade K (J.2.4.1) is a genetic branch of H3N2 with 11 mutations in hemagglutinin compared with the A/H3N2/Croatia/10136RV/2023 (H3N2 CR/23) vaccine strain, of which 8 mutations are on the hemagglutinin head surface (...) (...). As of February 2026, influenza A viruses currently represent approximately 96.3% of circulating influenza strains in the US, with H3N2 accounting for 88.4% of influenza isolates and subclade K comprising 91.5% of H3N2 isolates. The rapid expansion of H3N2 subclade K represents a major public health concern. This study reports antibody responses to H3N2 subclade K and other influenza strains before and after influenza vaccination.

(...)

Source: 

Link: https://jamanetwork.com/journals/jama/article-abstract/2846268

____

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 11 '26)

 

Biochemistry

1. VOGET R, Gutschow M
   Early Kinetic Characterization of SARS-CoV-2 Main Protease Inhibitors: A Review and Guidance for Biochemical Assessments.
   Biochemistry. 2026;65:860-881.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

2. MILLER AC, Boonstra DE, Cavanaugh JE, Boikos C, et al
   Disease burden associated with influenza activity at the population level.
   Epidemiol Infect. 2026 Apr 6:1-28. doi: 10.1017/S0950268826101320.
   PubMed        
   
   
3. ABUNIJELA S, Greiner T, Haas W, Kerber R, et al
   Frequency, dynamics, and duration of faecal shedding in SARS-CoV-2-infected individuals, a scoping review.
   Epidemiol Infect. 2026;154:e44.
   PubMed         Abstract available
   
   

   
   J Exp Med

4. MATHEW NR, Gailleton R, Scharf L, Schon K, et al
   Nasal CD4+ tissue-resident memory T cells provide cross-protective immunity to influenza.
   J Exp Med. 2026;223:e20251793.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. ULANOWICZ CJ, Alarcon PC, Damen MSMA, Wayland JL, et al
   Distinct inflammatory programming of thoracic cavity white adipose immune cells regulates influenza pathogenesis.
   J Infect Dis. 2026 Apr 7:jiag201. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   N Engl J Med

6. PARDO-SECO J, Martinon-Torres F
   High-Dose Influenza Vaccine and Hospitalizations in Older Adults. Reply.
   N Engl J Med. 2026;394:1454.
   PubMed        
   
   
7. JOHANSEN ND, Biering-Sorensen T
   High-Dose Influenza Vaccine and Hospitalizations in Older Adults. Reply.
   N Engl J Med. 2026;394:1454.
   PubMed        
   
   
8. KANEDA Y, Fujikawa T
   High-Dose Influenza Vaccine and Hospitalizations in Older Adults.
   N Engl J Med. 2026;394:1453-1454.
   PubMed        
   
   
9. CHEN HY, Liao JC, Yong SB
   High-Dose Influenza Vaccine and Hospitalizations in Older Adults.
   N Engl J Med. 2026;394:1453.
   PubMed        
   
   

   
   Pediatrics

10. OLSON SM, Ahmad HM, Wielgosz K, Michaels MG, et al
    Pediatric Vaccine Effectiveness Against Influenza Hospitalization And Outpatient Visits: 2021-2024.
    Pediatrics. 2026 Apr 6:e2025073973. doi: 10.1542/peds.2025-073973.
    PubMed         Abstract available
    
    
11. LUCACCIONI H, Maurel M, Perez-Gimeno G, Buda S, et al
    Influenza Vaccine Effectiveness in European Primary Care Pediatric Practices: 2022-2024.
    Pediatrics. 2026 Apr 6:e2025072907. doi: 10.1542/peds.2025-072907.
    PubMed         Abstract available
    
    

    
    PLoS One

12. ANTAO V, Krueger P, Meaney C, Kwong JC, et al
    Predictors of burnout among academic family medicine faculty: Looking back to plan forward.
    PLoS One. 2026;21:e0344702.
    PubMed         Abstract available
    
    
13. SPINOS D, Beech T, Lee J, Coulson C, et al
    Referral to treatment times in the National Health Service of England: A five-year analysis of the impact of the COVID-19 Pandemic and socioeconomic deprivation and future implications for Ear, Nose and Throat service delivery.
    PLoS One. 2026;21:e0346596.
    PubMed         Abstract available
    
    
14. SHARBAYTA SS, Jo Y, Jung J, Buonomo B, et al
    The impact of human behavioral adaptation stratified by immune status on COVID-19 spread with application to South Korea.
    PLoS One. 2026;21:e0345642.
    PubMed         Abstract available
    
    
15. GRAFF I, Berger M, Schmid M, Kogej M, et al
    A decade of triage with the Manchester Triage System-The MTS big data study.
    PLoS One. 2026;21:e0344598.
    PubMed         Abstract available
    
    
16. FELLER RL, Narraway CL, Burslem DF, Colucci-Gray L, et al
    Private garden uses and associated mental well-being benefits during the first UK Covid-19 lockdown - a social media investigation.
    PLoS One. 2026;21:e0289446.
    PubMed         Abstract available
    
    
17. PAN C, Shen W
    Revisiting price linkages between London and Shanghai base metal futures markets: A time-frequency connectedness analysis.
    PLoS One. 2026;21:e0346602.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

18. HA J, Sharma P, Ta S, Tsukuda S, et al
    Hypoxia inducible factors regulate pneumovirus replication by enhancing innate immune sensing.
    Proc Natl Acad Sci U S A. 2026;123:e2506647123.
    PubMed         Abstract available
    
    
19. PARENTI NA, Cusic R, Renner DM, Jackson N, et al
    SARS-CoV-2 and MERS-CoV disrupt host protein synthesis via nsp1 with differential effects on the integrated stress response.
    Proc Natl Acad Sci U S A. 2026;123:e2536296123.
    PubMed         Abstract available
    
    

    
    Vaccine

20. MCCULLOUGH R, Reid A, Smyth D, O'Neill MT, et al
    Leadership matters: ward manager vaccination status influences nursing staff influenza vaccine uptake.
    Vaccine. 2026;80:128541.
    PubMed         Abstract available
    
    
21. ZHANG J, Gong C, Xu Z, Han R, et al
    Multi-mode spatial accessibility to vaccination services and its impact on influenza-related hospitalisations among older adults.
    Vaccine. 2026;80:128540.
    PubMed         Abstract available
    
    

    
    Virus Res

22. WU Y, Sun W, Xia Y, Feng Y, et al
    The influenza B virus candidate vaccine expressing H3 hemagglutinin developed in suspension MDCK cells confers protection against lethal H3N2 avian influenza in BALB/c mice.
    Virus Res. 2026;367:199722.
    PubMed         Abstract available
    

Predicting the #antigenic #evolution of seasonal #influenza viruses using phylogenetic #convergence

 

Abstract

The antigenic evolution of human seasonal influenza viruses is primarily driven by single amino acid substitutions immediately adjacent to the receptor binding site in the hemagglutinin (HA) protein. The ability to predict these substitutions would allow vaccine strains to be selected with an understanding of likely future antigenic variation. Here, we estimate the effect of HA substitutions on viral fitness using measurements of convergent evolution in a large phylogeny. We show that the substitutions which have historically caused major antigenic changes in H3N2 influenza viruses were nearly always one of few substitutions near the HA receptor binding site estimated to be under positive selection in sequences collected before the antigenic transition, based on convergent acquisition of the substitution in multiple independent lineages. Furthermore, this signal predates the establishment of the major clade containing the antigenic substitution by more than one year, so is highly informative for prospective prediction.

Competing Interest Statement

The authors have declared no competing interest.

Funder Information Declared

National Institute of Allergy and Infectious Diseases, https://ror.org/043z4tv69, 75N93021C00014

National Institutes of Health, https://ror.org/01cwqze88, R01AI165818

Medical Research Council, https://ror.org/03x94j517, MR/Y004337/1

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.04.10.717627v1

____

#USA, Weekly #US #Influenza #Surveillance #Report: Key Updates for Week 13, ending April 4, 2026 (#CDC, summary)

 

(...)

Key Points

-- Seasonal influenza activity continues to decrease in most areas of the country. 

- Influenza A activity is low across all HHS regions while the amount of and trends in influenza B activity vary by region.

-- Influenza A(H3N2) viruses are the most frequently reported influenza viruses overall this season.

-- Among 2,166 influenza A(H3N2) viruses collected since September 28, 2025, that underwent additional genetic characterization at CDC, 92.8% belonged to subclade K.

-- The cumulative influenza-associated hospitalization rate overall in FluSurv-NET is the third highest since the 2010-2011 season. 

- Children younger than 18 years have the second highest cumulative hospitalization rate for that age group since the 2010-2011 season.

-- Twelve influenza-associated pediatric deaths occurring during the 2025-2026 season were reported to CDC this week, bringing the season total to 139 reported influenza-associated pediatric deaths.

-- Among children who were eligible for influenza vaccination and with known vaccination status, approximately 85% of reported pediatric deaths this season have occurred in children who were not fully vaccinated against influenza.

-- CDC's in-season severity assessment framework classified the season as moderate across all ages. 

- CDC also assesses severity by three age groups: pediatric (0-17 years), adult (18-64 years), and older adults (≥65 years). 

- At this point in the season, the pediatric age group is classified as having high severity, while both the adult and older adult age groups are classified as having moderate severity. 

- These assessments are conducted each week during the season, and the season's severity assessment can change if activity should increase again.

-- CDC estimates that there have been at least 31 million illnesses, 370,000 hospitalizations, and 23,000 deaths from flu so far this season.

-- Influenza (flu) vaccination has been shown to reduce the risk of flu and its potentially serious complications. 

- There is still time to get vaccinated against flu this season. 

- Approximately 135 million doses of influenza vaccine have been distributed in the United States this season.

-- There are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for patients at higher risk for flu-related complications.1

-- Influenza viruses are among several viruses contributing to respiratory disease activity. CDC provides updated, integrated information about COVID-19, flu, and respiratory syncytial virus (RSV) activity on a weekly basis.

-- No new avian influenza A(H5) infections were reported to CDC this week. To date, person-to-person transmission of influenza A(H5) viruses has not been identified in the United States.

(...)

Source: 

Link: https://www.cdc.gov/fluview/surveillance/2026-week-13.html

____